Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Dusseldorf - Delayed Quote EUR

Eli Lilly and Co (LLY0.DU)

Compare
20.80
+0.40
+(1.96%)
At close: February 21 at 7:30:55 PM GMT+1
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
45,042,700
45,042,700
34,124,100
28,541,400
28,318,400
Cost of Revenue
8,418,300
8,418,300
7,082,200
6,629,800
7,312,800
Gross Profit
36,624,400
36,624,400
27,041,900
21,911,600
21,005,600
Operating Expense
19,122,700
19,122,700
16,254,600
13,258,300
13,072,600
Operating Income
17,501,700
17,501,700
10,787,300
8,653,300
7,933,000
Net Non Operating Interest Income Expense
-605,400
-605,400
-312,300
-268,800
-314,400
Other Income Expense
-4,215,900
-4,215,900
-3,920,400
-1,578,100
-1,463,100
Pretax Income
12,680,400
12,680,400
6,554,600
6,806,400
6,155,500
Tax Provision
2,090,400
2,090,400
1,314,200
561,600
573,800
Net Income Common Stockholders
10,590,000
10,590,000
5,240,400
6,244,800
5,581,700
Diluted NI Available to Com Stockholders
10,590,000
10,590,000
5,240,400
6,244,800
5,581,700
Basic EPS
0.32
--
0.16
0.18
0.16
Diluted EPS
0.32
--
0.16
0.18
0.16
Basic Average Shares
33,015,739.76
--
32,970,795.20
34,833,208.39
34,960,453.55
Diluted Average Shares
33,142,361.72
--
33,113,950.59
34,833,208.39
34,960,453.55
Total Operating Income as Reported
12,899,000
--
--
--
--
Total Expenses
27,541,000
27,541,000
23,336,800
19,888,100
20,385,400
Net Income from Continuing & Discontinued Operation
10,590,000
10,590,000
5,240,400
6,244,800
5,581,700
Normalized Income
14,089,067.50
14,089,067.50
8,346,672.30
7,678,804.60
6,955,351.50
Interest Income
175,200
175,200
173,600
62,800
25,400
Interest Expense
780,600
780,600
485,900
331,600
339,800
Net Interest Income
-605,400
-605,400
-312,300
-268,800
-314,400
EBIT
13,461,000
13,461,000
7,040,500
7,138,000
6,495,300
EBITDA
15,227,600
15,227,600
8,567,800
8,660,500
8,042,900
Reconciled Cost of Revenue
8,418,300
8,418,300
7,082,200
6,629,800
7,312,800
Reconciled Depreciation
1,766,600
1,766,600
1,527,300
1,522,500
1,547,600
Net Income from Continuing Operation Net Minority Interest
10,590,000
10,590,000
5,240,400
6,244,800
5,581,700
Total Unusual Items Excluding Goodwill
-4,190,500
-4,190,500
-3,887,700
-1,563,800
-1,514,500
Total Unusual Items
-4,190,500
-4,190,500
-3,887,700
-1,563,800
-1,514,500
Normalized EBITDA
19,418,100
19,418,100
12,455,500
10,224,300
9,557,400
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-691,432.50
-691,432.50
-781,427.70
-129,795.40
-140,848.50
12/31/2021 - 3/28/2024

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

AMG.HA Amgen Inc
286.85
+1.34%
 
BRM.MU Bristol-Myers Squibb Co
52.86
+0.69%
 
D4S.MU Daiichi Sankyo Co Ltd
21.80
-0.59%
 
ABBV34.SA AbbVie Inc.
72.27
+1.22%
 
ORNAV.HE Orion Oyj
51.80
0.00%
 
NOVNEE.SW Novartis AG
98.04
+1.42%
 
COPNz.XC
 
0O59.IL Sanofi
104.04
+0.64%
 
SNW.F Sanofi
103.16
+0.19%
 
NOTA.F Novartis AG
100.00
-0.50%